Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025

Immutep ( (IMMP) ) has shared an announcement.

On October 20, 2025, Immutep Limited presented two posters at the ESMO Congress 2025, showcasing promising results from the INSIGHT-003 trial. The trial demonstrated that the combination of eftilagimod alfa (efti) with KEYTRUDA and chemotherapy significantly improved response rates in first-line non-small cell lung cancer (1L NSCLC) patients, particularly those with low or no PD-L1 expression. This advancement could potentially redefine the treatment paradigm for 1L NSCLC, offering new hope for patients with high unmet needs. The company is also progressing with its pivotal TACTI-004 Phase III trial, which aims to further validate efti’s efficacy and safety in a larger patient population.

The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

Immutep’s overall stock score is primarily influenced by its challenging financial performance, marked by persistent losses and negative cash flows. The technical analysis provides some positive momentum, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not impact the score.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. It is a leader in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to bring innovative treatment options to patients and maximize shareholder value.

Average Trading Volume: 116,588

Technical Sentiment Signal: Buy

Current Market Cap: $278M

For an in-depth examination of IMMP stock, go to TipRanks’ Overview page.